Red yeast rice products – legitimate concerns?

Red yeast rice products – legitimate concerns?

Red yeast rice products – legitimate concerns?

High blood lipid levels together with high blood pressure and diabetes are among the highest risks for coronary heart disease. In particular, an elevated cholesterol level promotes the progression of atherosclerotic processes. Therapeutically, it is mainly statins which are used to lower cholesterol levels. The use of dietary supplements made of red yeast rice, also called red fermented rice or red mold rice, as an alternative is currently the focus of a critical consideration of the ingredient Monakolin K.

Proprietary medicinal products based on the Statin group of drugs inhibit the key enzyme that converts the HMG-CoA produced by cholesterol biosynthesis into mevalonate. Due to reduced cholesterol synthesis, LDL cholesterol is increasingly broken down and HDL is increasingly formed. In addition, other pleiotropic effects, such as anti-inflammatory, antioxidant or direct vascular effects, are described in the literature.

The substances available on the market are considerably different in potency as well as side effects and interactions. The most significant side effects range from mild muscle pain up to myopathy with an increase in creatine kinase. The most dangerous complication is the extremely rare rhabdomyolysis which is a disintegration of striated muscle.

It should be noted in this context, however, that in view of the millions of prescriptions of these drugs, they are generally considered to be a very safe class of drugs.

Red yeast rice: Similar side effects

Alternatively, red yeast rice is offered in the form of dietary supplements or supplemented balanced diets. Red yeast rice is not a separate rice variety, but produced by the fermentation of ordinary rice with a certain mold fungi of the Monascus genus. During the fermentation, red dyes and various other potentially pharmacologically and toxicologically active ingredients are produced. The effective ingredient in these products is monacolin K which is identical to the drug Lovastatin.

Accordingly, in contrast to partially false medial representations, when taking products with red yeast rice there is a comparable effect, even if significantly reduced, and the potential for similar side effects and interactions as with using statins as drugs is to be assumed.

The prodrug Lovastatin, after gastrointestinal absorption and hydrolysis into hydroxyacid, is metabolised mainly in the liver by CYP-3A4. Hence, there are numerous interactions.

Strong CYP-3A4 inhibitors, in particular, can increase the risk of myopathy by strongly increasing the inhibitory activity of the HMG-CoA reductase in plasma during Lovastatin or red yeast rice therapy. These inhibitors include, for example, Cyclosporin, Itraconazole, Clarithromycin, Verapamil, Aprepitant, Amiodarone as well as HIV protease inhibitors such as Ritonavir and other cholesterol lowering agents such as Fibrates.

If grapefruit juice, known for interactions, is consumed in large amounts, there may also be a significant increase in HMG-CoA reductase inhibitory activity. Furthermore, there is clear evidence that Lovastatin inhibits the membrane transport protein P-glycoprotein, which plays an important role in the detoxification of drugs. This efflux transporter, which is predominantly found in excretory tissues, actively transports not only endogenous substances, such as steroids and cytokines, but also potentially toxic xenobiotics, out of cells. The inhibitory effect of Monacolin K (Lovastatin) on this transporter can thus also significantly influence the bioavailability and the distribution of drugs.

There is also evidence in the literature of the widely varying ratio of Monacolin K and Monacolin K acid in various products. This situation represents an additional factor of uncertainty because Monacolin K acid, which is the active form of Monacolin K, is much more readily absorbed. Therefore, the bioavailability of these products is difficult to estimate because the biological effect is not determined solely by the content of Manokolin K.

Misleading reporting

Misrepresentations in the media can suggest to patients that an adequate intake of red yeast rice products could provide sufficient treatment. However, this is grossly negligent, especially in the secondary prophylaxis of cardiovascular events which requires sufficient efficacy levels of a potent statin for therapeutic success.

One company went so far as to recommend the treatment of elevated cholesterol levels with red yeast rice products to patients who cannot tolerate statin therapy!

It should also be noted that dietary supplements are often considered by consumers to be less dangerous. This can be very deceptive in this case. Statins, and thus also red yeast rice products, are generally contraindicated during pregnancy and lactation due to their teratogenicity observed in animal experiments.

The literature also points to a lack of standardisation of monacolin levels as well as to the detection of nephrotoxic mycotoxin citrin. Another major factor of uncertainty is the taking of the drugs outside of medical control and the fact that there is no systematic recording of adverse effects, as required by law for authorised drugs.

Taking red yeast rice products and statins at the same time can easily lead to overdoses and side effects. Incidentally, Lovastatin should also be used with caution in patients who consume significant amounts of alcohol and/or have a history of liver disease.

It is recommended that red yeast rice products are only given out with appropriate warnings as they have the same clinically relevant risk potential as statins.


  1. Klimek M et al.: Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. P T. 2009;34(6): 313-317
  2. Lin JS: An alternative treatment of hyperlipidemia with red yeast rice: a case report, J Med Case Rep. 2010 Jan 8;4: 4
  3. Freissmuth M et al.: Pharmakologie und Toxikologie: Von den molekularen Grundlagen zur Pharmakotherapie. Springer Verlag. 2016: 499-501
  4. Becker DJ et al.: Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150(12): 830-839
  5. Lin CC et al.: Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol. 2005;153(5): 679-686
  6. Ji X et al.: Citrinin Determination in Red Fermented Rice Products by Optimized Extraction Method Coupled to Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). J Food Sci. 2015 Jun;80(6): T1438-44
  7. Prasad GV et al.: Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 2002; 74(8): 1200- 1201
  8. Smith DJ et al.: Chinese red rice-induced myopathy. South Med J. 2003;96: 1265-1267
  9. Lapi F et al.: Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol. 2008;66(4): 572-574
  10. Polsani, V. R. et al.: A case report of myopathy from consumption of red yeast rice. Journal of clinical lipidology 2008, 2, 60-62
  11. Mueller, P. S.: Symptomatic myopathy due to red yeast rice. Annals of internal medicine 2006, 145, 474-475
  12. Tonner P. H. et al.: Pharmakotherapie in der Anästhesie und Intensivmedizin. Springer Verlag. 2011: 261-262
  13. Lovastatin Hexal 20 mg-Tabletten. Fachinformation. Austria Codex. Österreichische Apotheker-Verlagsgesellschaft m.b.H. 2018
  14. BfArM: Pressemitteilung 3/16 – BfArM warnt erneut vor Red Rice-Nahrungsergänzungsmitteln: Produkte ab einer Tagesdosis von 5 mg Monakolin K sind als Arzneimittel einzustufen. 2016
  15. FDA: FDA warns consumers to avoid Red Yeast Rice Products promoted on internet as treatments for high cholesterol Products found to contain unauthorized drug. 09.08.2007
  16. swissmedic: Vermarktung von Präparaten mit Monascus purpureus (Rotschimmelreis, rote Reishefe) ist in der Schweiz nicht zulässig. 12.3.2014
  17. BVL, BfArM: Stellungnahme der gemeinsamen Expertenkommission BVL/BfArM – Einstufung von Rotschimmelreisprodukten. 02/2016
  18. PHYTO Therapie 1/13: 13
  19. Hong SP. Et al.: Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. J Pharm Pharmacol. 2011 Jan;63(1): 129-135.
  20. Choi DH. Et al.: Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. Eur J Clin Pharmacol. 2010 Mar;66(3): 285-290
  21. Becker, D. J. et al.: Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Annals of internal medicine 2009, 150, 830-839, W147-839
  22. Li, Y. G. et al.: Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. Journal of pharmaceutical and biomedical analysis 2004, 35: 1101-1112
  23. Gordon, R. Y. et al.: Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Archives of internal medicine 2010, 170:1722-1727
  24. Heber, D. et al.: An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med. 2001 Apr;7(2): 133-139
  25. Farkouh A. und Baumgärtel C.: Produkte aus Rotem Reis: Sind gesundheitliche Bedenken berechtigt? Österreichische Apotheker-Zeitung. 2018 Dez 26: 44-47


Apotheke zum Schutzengel © 2015 All Rights Reserved.

Impressum | Datenschutzerklärung